Company: PHR
Filing Date: 2025-09-05
Form Type: 10-Q
Source: 0001412408-25-000062
Chunk: 164

Company: Phreesia, Inc.
Filing Date: 2025-09-05
Form: 10-Q
Item: Part I, Item 8
Chunk 164
---
) per share when the effect of including the securities would be anti-dilutive. The following potential shares of common stock, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net income (loss) per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:Three months endedJuly 31,Six months endedJuly 31,2025202420252024Stock options to purchase common stock, restricted stock and performance stock awards876,566 6,795,068 5,930,619 6,795,068 Employee stock purchase plan54,373 82,784 52,147 82,784 Total930,939 6,877,852 5,982,766 6,877,852 

14. Related party transactions

For the three months ended July 31, 2025 and 2024, the Company recognized revenue totaling $273 and $343, respectively, for advertisements placed by a pharmaceutical company. For the six months ended July 31, 2025 and 

31

Table of Contents

2024, the Company recognized revenue totaling $461 and $671, respectively, for advertisements placed by the same pharmaceutical company. One of the Company's independent members of its board of directors serves on the board of directors for this pharmaceutical company. As of July 31, 2025 and January 31, 2025, accounts receivable from the pharmaceutical company totaled $116.

15. Segments and geographic information

Operating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company defines the term “chief operating decision maker” to be its Chief Executive Officer. The Company’s Chief Executive Officer reviews the financial information presented on an entire company basis for purposes of allocating resources and evaluating its financial performance. Accordingly, the Company has determined that it operates in a single reportable operating segment, managed on a consolidated basis, which the Company refers to as the Technology solutions segment.The Technology solutions segment provides comprehensive software solutions that improve the operational and financial performance of healthcare organizations and improve health outcomes by helping patients take a more active role in their care. The Technology solutions segment’s solutions include SaaS-based integrated tools that manage patient access, registration and payments. Additionally, the Technology solutions segment has tools to communicate with patients about their health, which have demonstrated increased rates of preventive care and vaccinations